3 Things to Loathe About GlaxoSmithKline plc (ADR) (GSK)

LONDON — There are things to love and loathe about most companies. Today, I’m going to tell you about three things to loathe about GlaxoSmithKline plc (ADR) (NYSE:GSK).

I’ll also be asking whether these negative factors make this FTSE 100 pharmaceuticals giant a poor investment today.

GlaxoSmithKline plc (ADR) (NYSE:GSK)

Long-term returns
GlaxoSmithKline plc (ADR) (NYSE:GSK)’s long-run total return for shareholders (capital appreciation and dividends over the past 10 years) has lagged behind that of the average FTSE 100 company. Furthermore, as the table below shows, GlaxoSmithKline plc (ADR) (NYSE:GSK) has been one of the poorer performers among its European big pharma peers.

Company Total return
over 10 years
(annualized)
Roche 9.4%
Novartis 8.6%
Sanofi 8.3%
GlaxoSmithKline 5.9%
AstraZeneca 5.3%

Margin pressures
GlaxoSmithKline plc (ADR) (NYSE:GSK), like all the established big pharma companies, faces what it calls ”intense competition” from generic products within all of its major markets. This is particularly true of the U.S., where GlaxoSmithKline plc (ADR) (NYSE:GSK) has its highest turnover and margins, both of which are now under pressure from generics.

The U.S. accounts for almost a third of group turnover, and in addition to the squeeze from generics, the country’s health care reforms are also putting pressure on GlaxoSmithKline plc (ADR) (NYSE:GSK)’s margins.

Finally, the company’s diversification into consumer health care has implications for group margins: the operating margin for pharmaceuticals and vaccines is running at over 36%, but the margin within the over-the-counter business is half that.

Concentration of risk
Another issue for GSK in the U.S. is that the sale of most of its products are made to a small number of wholesalers. In fact, more than 80% of the group’s U.S. pharmaceuticals and vaccines turnover comes from just three wholesalers.

Trade receivables due from these three (that’s the money they owe GSK) amounted to 815 million pounds — the equivalent of 17 pence a share — at the latest reckoning. This concentration of credit risk could potentially, as GSK says, ”materially and adversely affect the Group’s financial results.”

A poor investment?
Many of the issues GSK faces are felt across the whole sector. Whether the sum of factors that constitute GSK’s particular variation on the theme put the company in a better or worse position than its peers is a moot point.

Two of the world’s top investors aren’t prepared to argue it. Instead, they prefer to hedge their bets in a sector where the theoretical strength of the different companies’ drugs pipelines isn’t a reliable guide to which products will actually turn out to be the biggest winners.

Legendary U.S. investor Warren Buffett and renowned U.K. fund manager Neil Woodford both choose to invest across several big pharma companies.

The article 3 Things to Loathe About GlaxoSmithKline originally appeared on Fool.com.

G.A. Chester has no position in any stocks mentioned. The Motley Fool recommends GlaxoSmithKline.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!